ClinicalTrials.gg
Sign In

Pheochromocytoma clinical trials

The registry lists 158 studies for Pheochromocytoma across more than 10 countries. 57 are recruiting or about to start. 91 of them are mainly about Pheochromocytoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Pheochromocytoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
56
Recruiting
43
Terminated
13
Active, not recruiting
11
Status unknown
10
Not yet recruiting
8

Phase

Phase 2
55
Phase 1
21
Phase 3
6
Phase 4
4
Early Phase 1
3

Where

United States
69
China
21
France
16
United Kingdom
10
Canada
9
Italy
8

Who runs them

National Cancer Institute (NCI) (15) · Peking Union Medical College Hospital (11) · Seoul National University Hospital (5) · Molecular Insight Pharmaceuticals, Inc. (5) · M.D. Anderson Cancer Center (4) · University of California, San Francisco (3) · British Columbia Cancer Agency (3) · Jagiellonian University (3)

What is being tested here

Drugs under test in Pheochromocytoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Belzutifan404
Lead PB-212303
Anlotinib104
Temozolomide104
3-Iodobenzylguanidine103
Lutetium Lu 177 dotatate103
Olaparib102
Phenoxybenzamine102
177Lu-octreotide, DOTA(0)-Tyr(3)-102
Florbenguane F-18102

Drug classes tested here Immune checkpoint inhibitors 3 open · Tyrosine kinase inhibitors (TKIs) 2 open · Alkylating agents 1 open · PARP inhibitors 1 open · mTOR inhibitors 4

Coming up

0phase 3 studies under way
13studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 43 Pheochromocytoma studies recruiting now, 22 (51%) set no upper age limit and 6 (14%) stop at 75 or younger. 19 (44%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (9%) take healthy volunteers.

Recruiting studies that take each age, of 43
AgeWomenMen
1014 (33%)14 (33%)
1841 (95%)41 (95%)
3042 (98%)42 (98%)
4042 (98%)42 (98%)
5042 (98%)42 (98%)
6542 (98%)42 (98%)
7540 (93%)40 (93%)
8533 (77%)33 (77%)

Across all 158 studies, recruiting or not: 16% stop at 75 or younger and 4% at 65; 35% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pheochromocytoma studies take

Of 28 phase 2 interventional studies under Pheochromocytoma, half reached primary completion within 92 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 292 mo36–157 · 28 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 158. Browse all 158 → or search them.